INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET -amplified NSCLC and first-line osimertinib resistance.

Autor: F Smit E; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Dooms C; Department of Respiratory Diseases & Respiratory Oncology Unit, University Hospitals Leuven, Leuven, Belgium., Raskin J; Department of Pulmonology & Thoracic Oncology, Antwerp University Hospital (UZA), Edegem, Belgium., Nadal E; Department of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain., Tho LM; Department of Oncology, Pantai Hospital, Kuala Lumpur, Malaysia., Le X; Department of Thoracic Head & Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Mazieres J; CHU de Toulouse, Institut Universitaire du Cancer, Toulouse, France., S Hin H; Hospital Tengku Ampuan Afzan, Pahang, Malaysia., Morise M; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan., W Zhu V; University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, CA, USA., Tan D; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., H Holmberg K; EMD Serono Research & Development Institute, Inc., MA, USA, an affiliate of Merck KGaA., Ellers-Lenz B; Department of Biostatistics, Merck Healthcare KGaA, Darmstadt, Germany., Adrian S; Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany., Brutlach S; Late Stage Development Operations, Merck Healthcare KGaA, Darmstadt, Germany., Schumacher KM; Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany., Karachaliou N; Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany., Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.

Publikováno v: Future oncology (London, England) [Future Oncol] 2022 Mar; Vol. 18 (9), pp. 1039-1054. Date of Electronic Publication: 2021 Dec 17.